A New Tool to Delay Type 1 Diabetes: What You Should Know About Teplizumab

For decades, type 1 diabetes has been managed after diagnosis, once the immune system has already destroyed most of the insulin-producing beta cells in the pancreas. Now, medicine is shifting toward earlier intervention. The FDA has approved teplizumab, marking the first drug shown to delay the onset of stage 3 type 1 diabetes—the stage at which symptoms typically appear and diagnosis is made.

This approval represents a meaningful change in how we think about type 1 diabetes, moving from treatment alone to disease-modifying therapy that can slow progression in the earliest detectable stages. However, it's important to understand what this means: teplizumab delays onset, it does not cure the disease or prevent it entirely.

Type 1 diabetes develops in stages. Stage 1 and stage 2 are characterized by the presence of autoimmune markers but no symptoms. Stage 3 is when blood sugar rises and symptoms appear, leading to diagnosis. Teplizumab is approved for children and adolescents with stage 3 type 1 diabetes and has also been studied in stage 2, when disease-modifying therapy might have the greatest impact.

Identifying people in early stages requires screening—blood tests that look for autoimmune markers suggesting type 1 diabetes risk. According to the latest clinical guidelines from the International Society for Pediatric and Adolescent Diabetes (ISPAD), screening and monitoring strategies are now part of the comprehensive care recommendations for at-risk children and adolescents.

A recent survey of adults and caregivers who received teplizumab offers insight into how people experience this new treatment. Nearly half of respondents had a family history of type 1 diabetes, and about one-third reported other autoimmune conditions. The top reason people sought both screening and treatment was the opportunity to delay stage 3 type 1 diabetes.

The responses were largely positive: 87% felt grateful to receive teplizumab, 72% believed it would help slow disease progression, and 60% felt it might make type 1 diabetes easier to manage once it developed. Over 80% said they would recommend the treatment or make the same decision for another family member. At the same time, most respondents continued to worry about diabetes progression, reflecting realistic expectations rather than false hope.

While teplizumab is the first FDA-approved disease-modifying therapy for type 1 diabetes, it is not the only approach being studied. Researchers are testing other monoclonal antibodies, therapies targeting specific immune signals, antigen-specific treatments, and immunomodulatory agents—some alone and some in combination.

A significant challenge has emerged: in people with stage 3 type 1 diabetes, many interventions have produced temporary improvements in beta-cell function, but these benefits have not lasted long-term. Ongoing research aims to refine which patients are most likely to benefit, identify new therapeutic targets, and develop treatments with more durable effects. The field is moving forward, but questions remain about optimizing timing, patient selection, and long-term outcomes.

If you have a family history of type 1 diabetes or are concerned about risk, discussing screening options with your healthcare provider is a reasonable first step. Screening can identify early stages of the disease before symptoms appear, which opens the door to considering disease-modifying therapies like teplizumab.

It's important to have realistic conversations about what these treatments can and cannot do. Teplizumab delays disease onset—a meaningful benefit—but it is not a cure and does not prevent type 1 diabetes entirely. Clinical guidelines from ISPAD now include evidence-based recommendations for screening, monitoring, and preservation strategies, reflecting the medical community's evolving approach to early intervention. As research continues, more options may become available, and our understanding of who benefits most will continue to improve.

Origin: Healio (News report). Evidence: News report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.